PMID- 28141765
DCOM- 20170418
LR  - 20180502
IS  - 1531-7021 (Electronic)
IS  - 1040-8738 (Linking)
VI  - 28
IP  - 3
DP  - 2017 May
TI  - Role of cytokines and treatment algorithms in retinopathy of prematurity.
PG  - 282-288
LID - 10.1097/ICU.0000000000000360 [doi]
AB  - PURPOSE OF REVIEW: Currently, severe retinopathy of prematurity (ROP) is
      diagnosed by clinical evaluation and not a laboratory test. Laser is still
      considered standard care. However, anti-vascular endothelial growth factor (VEGF)
      agents are being used and there are questions whether and/or if to use them, what
      dose or type of agent should be considered and what agent may be most beneficial 
      in specific cases. Also unclear are the effects of laser or anti-VEGF on severe
      ROP, refractive outcomes or infant development. This article reviews recent
      studies related to these questions and other trials for severe ROP. RECENT
      FINDINGS: Imaging studies identify biomarkers of risk (plus disease, stage 3 ROP,
      and ROP in zone I). Intravitreal bevacizumab or ranibizumab are reported
      effective in treating aggressive posterior ROP in small series. Recurrences and
      effects on myopia vary among studies. Use of anti-VEGF agents affects cytokines
      in the infant blood and reduces systemic VEGF for up to 2 months, raising
      potential safety concerns. The effects of treatment vary based on infant size and
      are not comparable. Evidence for most studies is not high. SUMMARY: Studies
      support experimental evidence that inhibiting VEGF reduces stage 3 ROP and
      peripheral avascular retina. Ongoing large-scale clinical trials may provide
      clarity for best treatments of severe ROP. Current guidelines hold for screening 
      and treatment for type 1 ROP.
FAU - Hartnett, M Elizabeth
AU  - Hartnett ME
AD  - John A. Moran Eye Center, University of Utah, Salt Lake City Utah, USA.
LA  - eng
GR  - P30 EY014800/EY/NEI NIH HHS/United States
GR  - R01 EY015130/EY/NEI NIH HHS/United States
PT  - Journal Article
PT  - Review
PL  - United States
TA  - Curr Opin Ophthalmol
JT  - Current opinion in ophthalmology
JID - 9011108
RN  - 0 (Angiogenesis Inhibitors)
RN  - 0 (Cytokines)
RN  - 0 (VEGFA protein, human)
RN  - 0 (Vascular Endothelial Growth Factor A)
RN  - 2S9ZZM9Q9V (Bevacizumab)
RN  - ZL1R02VT79 (Ranibizumab)
SB  - IM
MH  - *Algorithms
MH  - Angiogenesis Inhibitors/metabolism/*therapeutic use
MH  - Bevacizumab/therapeutic use
MH  - Cytokines/*physiology
MH  - Humans
MH  - Infant
MH  - Infant, Newborn
MH  - Intravitreal Injections
MH  - Ranibizumab/therapeutic use
MH  - Retinopathy of Prematurity/diagnosis
MH  - Vascular Endothelial Growth Factor A/antagonists & inhibitors
PMC - PMC5495148
MID - NIHMS873750
EDAT- 2017/02/01 06:00
MHDA- 2017/04/19 06:00
CRDT- 2017/02/01 06:00
PHST- 2017/02/01 06:00 [pubmed]
PHST- 2017/04/19 06:00 [medline]
PHST- 2017/02/01 06:00 [entrez]
AID - 10.1097/ICU.0000000000000360 [doi]
PST - ppublish
SO  - Curr Opin Ophthalmol. 2017 May;28(3):282-288. doi: 10.1097/ICU.0000000000000360.